177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians

PurposeThere is increasing evidence for convincing efficacy and safety of 177Lu-labled prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for metastatic castration-resistant prostate cancer (mCRPC). However, data are not available regarding the feasibility of 177Lu-labled...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Frontiers in oncology 2022-03, Vol.12, p.835956-835956
Hauptverfasser:	Bu, Ting, Zhang, Lulu, Yu, Fei, Yao, Xiaochen, Wu, Wenyu, Zhang, Pengjun, Shi, Liang, Zang, Shiming, Meng, Qingle, Ni, Yudan, Shao, Guoqiang, Qiu, Xuefeng, Ai, Shuyue, Jia, Ruipeng, Guo, Hongqian, Wang, Feng
Format:	Artikel
Sprache:	eng
Schlagworte:	Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!